BRCA2 has a critical role in DNA repair, and mutations in BRCA2 are a known risk factor for the development of breast cancer in men.3 Two pivotal trials demonstrated the role of PARP inhibitors in the treatment of BRCA-mutated metastatic breast cancer [25, 26]. This evidence concerns the gene BRCA2 and breast carcinoma.